GenLabMeds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://genlabmeds.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide, and tirzepatide. As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 355(a), 352(f)(1), 331(a) and 331(d)]. In addition, your claims concerning compounded retatrutide, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)] resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “Your compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B. Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.”

2. 2

   “There are no FDA-approved applications on file for your compounded retatrutide drug products. Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.”

3. 3

   “The following claims concerning your compounded retatrutide, semaglutide, and tirzepatide products appear on your website:”

4. 4

   “Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound”

5. 5

   “Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy”

6. 6

   “What does the treatment plan generally look like? The standard, FDA-approved dosing schedule for Retatrutide is: Month 1: 0.25 mg per week…”

7. 7

   “Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.”

8. 8

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

genlabmeds.com resolved and returned a live, fully served storefront to a direct fetch on 2026-08-09 — a rendered homepage with a working cart, checkout and account pages, rather than a placeholder, a parking page or an error. That is a check of whether the site is up; it is not a check of anything the letter alleges.

A claimed dosing schedule is not the usual kind of marketing line. “Same active ingredient as” is an argument about chemistry that a careful reader can at least interrogate. A schedule presented as FDA-approved is different: it asserts that a regulator reviewed a way of using the product and signed it off. Here there was nothing for that assertion to point at, because FDA has approved no application for the product at all — which is the other half of the same letter. That is what makes it the most useful entry in this index. A shopper has no way to audit it from the outside; an invented approval is written in exactly the same words as a real one, and it arrives attached to a price. The practical habit it argues for is narrow and checkable: when a page says approved, ask approved for what, and look for the product and the application holder, not the ingredient. What the letter does not do is make any finding about how these products were made or what was in them. Its findings are about approval status and about what the page told people.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence GenLabMeds failed to respond.